Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.
about
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group.Targeted therapies in breast cancer: are heart and vessels also being targeted?Late toxicities and outcomes of adjuvant radiotherapy combined with concurrent bevacizumab in patients with triple-negative non-metastatic breast cancer.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.Incidence, Diagnosis, and Management of QT Prolongation Induced by Cancer Therapies: A Systematic Review.
P2860
Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Addition of bevacizumab to thr ...... for early stage breast cancer.
@en
type
label
Addition of bevacizumab to thr ...... for early stage breast cancer.
@en
prefLabel
Addition of bevacizumab to thr ...... for early stage breast cancer.
@en
P2093
P2860
P1476
Addition of bevacizumab to thr ...... for early stage breast cancer.
@en
P2093
Barrett H Childs
Brooke R Daniel
D Randolph Drosick
David Waterhouse
Denise A Yardley
Howard Burris
Lowell Hart
Patrick Murphy
Robert Whorf
Suprith Badarinath
P2860
P2888
P304
P356
10.1007/S10549-013-2764-Y
P407
P577
2013-11-21T00:00:00Z